nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—Methylprednisolone—multiple sclerosis	0.0954	0.232	CbGbCtD
Naltrexone—ABCB1—Mitoxantrone—multiple sclerosis	0.0696	0.169	CbGbCtD
Naltrexone—ABCB1—Betamethasone—multiple sclerosis	0.062	0.151	CbGbCtD
Naltrexone—ABCB1—Prednisolone—multiple sclerosis	0.0612	0.149	CbGbCtD
Naltrexone—ABCB1—Prednisone—multiple sclerosis	0.0578	0.141	CbGbCtD
Naltrexone—ABCB1—Dexamethasone—multiple sclerosis	0.0361	0.0878	CbGbCtD
Naltrexone—ABCB1—Methotrexate—multiple sclerosis	0.029	0.0705	CbGbCtD
Naltrexone—Naloxone—TLR4—multiple sclerosis	0.00618	0.889	CrCbGaD
Naltrexone—OPRM1—nerve—multiple sclerosis	0.000909	0.191	CbGeAlD
Naltrexone—Naloxone—ALB—multiple sclerosis	0.000772	0.111	CrCbGaD
Naltrexone—OPRM1—brainstem—multiple sclerosis	0.00039	0.0819	CbGeAlD
Naltrexone—Conjunctivitis—Methotrexate—multiple sclerosis	0.000338	0.000788	CcSEcCtD
Naltrexone—Confusional state—Methylprednisolone—multiple sclerosis	0.000338	0.000788	CcSEcCtD
Naltrexone—Immune system disorder—Prednisone—multiple sclerosis	0.000338	0.000787	CcSEcCtD
Naltrexone—Malaise—Dexamethasone—multiple sclerosis	0.000337	0.000785	CcSEcCtD
Naltrexone—Malaise—Betamethasone—multiple sclerosis	0.000337	0.000785	CcSEcCtD
Naltrexone—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000336	0.000783	CcSEcCtD
Naltrexone—Oedema—Triamcinolone—multiple sclerosis	0.000336	0.000783	CcSEcCtD
Naltrexone—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000335	0.000781	CcSEcCtD
Naltrexone—Syncope—Dexamethasone—multiple sclerosis	0.000335	0.000781	CcSEcCtD
Naltrexone—Syncope—Betamethasone—multiple sclerosis	0.000335	0.000781	CcSEcCtD
Naltrexone—Infection—Triamcinolone—multiple sclerosis	0.000334	0.000778	CcSEcCtD
Naltrexone—Infection—Methylprednisolone—multiple sclerosis	0.000333	0.000776	CcSEcCtD
Naltrexone—Shock—Triamcinolone—multiple sclerosis	0.000331	0.00077	CcSEcCtD
Naltrexone—Insomnia—Prednisolone—multiple sclerosis	0.00033	0.00077	CcSEcCtD
Naltrexone—Alopecia—Prednisone—multiple sclerosis	0.00033	0.00077	CcSEcCtD
Naltrexone—Shock—Methylprednisolone—multiple sclerosis	0.00033	0.000769	CcSEcCtD
Naltrexone—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000329	0.000767	CcSEcCtD
Naltrexone—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000329	0.000766	CcSEcCtD
Naltrexone—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000328	0.000765	CcSEcCtD
Naltrexone—Loss of consciousness—Betamethasone—multiple sclerosis	0.000328	0.000765	CcSEcCtD
Naltrexone—Epistaxis—Methotrexate—multiple sclerosis	0.000328	0.000765	CcSEcCtD
Naltrexone—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000328	0.000765	CcSEcCtD
Naltrexone—Paraesthesia—Prednisolone—multiple sclerosis	0.000328	0.000765	CcSEcCtD
Naltrexone—Tachycardia—Triamcinolone—multiple sclerosis	0.000328	0.000764	CcSEcCtD
Naltrexone—Mental disorder—Prednisone—multiple sclerosis	0.000327	0.000763	CcSEcCtD
Naltrexone—Nausea—Azathioprine—multiple sclerosis	0.000327	0.000763	CcSEcCtD
Naltrexone—Tachycardia—Methylprednisolone—multiple sclerosis	0.000327	0.000763	CcSEcCtD
Naltrexone—Skin disorder—Methylprednisolone—multiple sclerosis	0.000326	0.000759	CcSEcCtD
Naltrexone—Malnutrition—Prednisone—multiple sclerosis	0.000325	0.000758	CcSEcCtD
Naltrexone—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000325	0.000757	CcSEcCtD
Naltrexone—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000324	0.000755	CcSEcCtD
Naltrexone—Convulsion—Dexamethasone—multiple sclerosis	0.000324	0.000754	CcSEcCtD
Naltrexone—Convulsion—Betamethasone—multiple sclerosis	0.000324	0.000754	CcSEcCtD
Naltrexone—Hypertension—Dexamethasone—multiple sclerosis	0.000323	0.000752	CcSEcCtD
Naltrexone—Hypertension—Betamethasone—multiple sclerosis	0.000323	0.000752	CcSEcCtD
Naltrexone—Asthenia—Mitoxantrone—multiple sclerosis	0.00032	0.000745	CcSEcCtD
Naltrexone—Myalgia—Betamethasone—multiple sclerosis	0.000318	0.000741	CcSEcCtD
Naltrexone—Myalgia—Dexamethasone—multiple sclerosis	0.000318	0.000741	CcSEcCtD
Naltrexone—Anxiety—Betamethasone—multiple sclerosis	0.000317	0.000739	CcSEcCtD
Naltrexone—Anxiety—Dexamethasone—multiple sclerosis	0.000317	0.000739	CcSEcCtD
Naltrexone—Discomfort—Betamethasone—multiple sclerosis	0.000314	0.000732	CcSEcCtD
Naltrexone—Discomfort—Dexamethasone—multiple sclerosis	0.000314	0.000732	CcSEcCtD
Naltrexone—Pain—Prednisolone—multiple sclerosis	0.000312	0.000728	CcSEcCtD
Naltrexone—Hepatitis—Methotrexate—multiple sclerosis	0.000312	0.000728	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—multiple sclerosis	0.00031	0.000722	CcSEcCtD
Naltrexone—Vision blurred—Prednisone—multiple sclerosis	0.000307	0.000715	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000306	0.000713	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000305	0.000712	CcSEcCtD
Naltrexone—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000305	0.000711	CcSEcCtD
Naltrexone—Oedema—Betamethasone—multiple sclerosis	0.000305	0.000711	CcSEcCtD
Naltrexone—Oedema—Dexamethasone—multiple sclerosis	0.000305	0.000711	CcSEcCtD
Naltrexone—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000305	0.000711	CcSEcCtD
Naltrexone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000305	0.00071	CcSEcCtD
Naltrexone—Insomnia—Triamcinolone—multiple sclerosis	0.000304	0.000708	CcSEcCtD
Naltrexone—Insomnia—Methylprednisolone—multiple sclerosis	0.000303	0.000707	CcSEcCtD
Naltrexone—Infection—Dexamethasone—multiple sclerosis	0.000303	0.000706	CcSEcCtD
Naltrexone—Infection—Betamethasone—multiple sclerosis	0.000303	0.000706	CcSEcCtD
Naltrexone—Ill-defined disorder—Prednisone—multiple sclerosis	0.000302	0.000703	CcSEcCtD
Naltrexone—Paraesthesia—Triamcinolone—multiple sclerosis	0.000302	0.000703	CcSEcCtD
Naltrexone—Feeling abnormal—Prednisolone—multiple sclerosis	0.000301	0.000702	CcSEcCtD
Naltrexone—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000301	0.000702	CcSEcCtD
Naltrexone—Shock—Betamethasone—multiple sclerosis	0.0003	0.000699	CcSEcCtD
Naltrexone—Shock—Dexamethasone—multiple sclerosis	0.0003	0.000699	CcSEcCtD
Naltrexone—OPRD1—nervous system—multiple sclerosis	0.0003	0.0629	CbGeAlD
Naltrexone—Dyspnoea—Triamcinolone—multiple sclerosis	0.0003	0.000698	CcSEcCtD
Naltrexone—Nervous system disorder—Betamethasone—multiple sclerosis	0.000299	0.000697	CcSEcCtD
Naltrexone—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000299	0.000697	CcSEcCtD
Naltrexone—Agitation—Prednisone—multiple sclerosis	0.000299	0.000697	CcSEcCtD
Naltrexone—Tachycardia—Dexamethasone—multiple sclerosis	0.000298	0.000693	CcSEcCtD
Naltrexone—Tachycardia—Betamethasone—multiple sclerosis	0.000298	0.000693	CcSEcCtD
Naltrexone—Angioedema—Prednisone—multiple sclerosis	0.000297	0.000693	CcSEcCtD
Naltrexone—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000295	0.000687	CcSEcCtD
Naltrexone—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000295	0.000687	CcSEcCtD
Naltrexone—Malaise—Prednisone—multiple sclerosis	0.000293	0.000684	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—multiple sclerosis	0.000292	0.00068	CcSEcCtD
Naltrexone—Syncope—Prednisone—multiple sclerosis	0.000292	0.00068	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—multiple sclerosis	0.000291	0.000679	CcSEcCtD
Naltrexone—Anorexia—Dexamethasone—multiple sclerosis	0.000291	0.000677	CcSEcCtD
Naltrexone—Anorexia—Betamethasone—multiple sclerosis	0.000291	0.000677	CcSEcCtD
Naltrexone—Urticaria—Prednisolone—multiple sclerosis	0.00029	0.000676	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—multiple sclerosis	0.00029	0.000676	CcSEcCtD
Naltrexone—Fatigue—Triamcinolone—multiple sclerosis	0.00029	0.000675	CcSEcCtD
Naltrexone—Fatigue—Methylprednisolone—multiple sclerosis	0.000289	0.000674	CcSEcCtD
Naltrexone—OPRD1—central nervous system—multiple sclerosis	0.000289	0.0606	CbGeAlD
Naltrexone—OPRK1—nervous system—multiple sclerosis	0.000287	0.0603	CbGeAlD
Naltrexone—Pain—Triamcinolone—multiple sclerosis	0.000287	0.00067	CcSEcCtD
Naltrexone—Loss of consciousness—Prednisone—multiple sclerosis	0.000286	0.000666	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—multiple sclerosis	0.000283	0.00066	CcSEcCtD
Naltrexone—Vomiting—Mitoxantrone—multiple sclerosis	0.000283	0.00066	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—multiple sclerosis	0.000282	0.000657	CcSEcCtD
Naltrexone—Convulsion—Prednisone—multiple sclerosis	0.000282	0.000657	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000281	0.000656	CcSEcCtD
Naltrexone—Hypertension—Prednisone—multiple sclerosis	0.000281	0.000655	CcSEcCtD
Naltrexone—Rash—Mitoxantrone—multiple sclerosis	0.000281	0.000654	CcSEcCtD
Naltrexone—Dermatitis—Mitoxantrone—multiple sclerosis	0.000281	0.000654	CcSEcCtD
Naltrexone—Chills—Methotrexate—multiple sclerosis	0.00028	0.000653	CcSEcCtD
Naltrexone—Headache—Mitoxantrone—multiple sclerosis	0.000279	0.00065	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000278	0.000647	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000278	0.000647	CcSEcCtD
Naltrexone—Myalgia—Prednisone—multiple sclerosis	0.000277	0.000645	CcSEcCtD
Naltrexone—Arthralgia—Prednisone—multiple sclerosis	0.000277	0.000645	CcSEcCtD
Naltrexone—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000277	0.000645	CcSEcCtD
Naltrexone—OPRK1—central nervous system—multiple sclerosis	0.000277	0.0581	CbGeAlD
Naltrexone—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000276	0.000644	CcSEcCtD
Naltrexone—Anxiety—Prednisone—multiple sclerosis	0.000276	0.000643	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—multiple sclerosis	0.000276	0.000643	CcSEcCtD
Naltrexone—Insomnia—Betamethasone—multiple sclerosis	0.000276	0.000643	CcSEcCtD
Naltrexone—Insomnia—Dexamethasone—multiple sclerosis	0.000276	0.000643	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000275	0.000641	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000274	0.000639	CcSEcCtD
Naltrexone—Paraesthesia—Dexamethasone—multiple sclerosis	0.000274	0.000638	CcSEcCtD
Naltrexone—Paraesthesia—Betamethasone—multiple sclerosis	0.000274	0.000638	CcSEcCtD
Naltrexone—Discomfort—Prednisone—multiple sclerosis	0.000274	0.000638	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—multiple sclerosis	0.000274	0.000638	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—multiple sclerosis	0.000272	0.000634	CcSEcCtD
Naltrexone—OPRK1—cerebellum—multiple sclerosis	0.00027	0.0568	CbGeAlD
Naltrexone—Hypersensitivity—Prednisolone—multiple sclerosis	0.000269	0.000627	CcSEcCtD
Naltrexone—Urticaria—Triamcinolone—multiple sclerosis	0.000267	0.000622	CcSEcCtD
Naltrexone—Urticaria—Methylprednisolone—multiple sclerosis	0.000266	0.000621	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—multiple sclerosis	0.000266	0.00062	CcSEcCtD
Naltrexone—Body temperature increased—Triamcinolone—multiple sclerosis	0.000266	0.000619	CcSEcCtD
Naltrexone—Oedema—Prednisone—multiple sclerosis	0.000266	0.000619	CcSEcCtD
Naltrexone—Anaphylactic shock—Prednisone—multiple sclerosis	0.000266	0.000619	CcSEcCtD
Naltrexone—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000265	0.000618	CcSEcCtD
Naltrexone—Decreased appetite—Dexamethasone—multiple sclerosis	0.000265	0.000618	CcSEcCtD
Naltrexone—Decreased appetite—Betamethasone—multiple sclerosis	0.000265	0.000618	CcSEcCtD
Naltrexone—Nausea—Mitoxantrone—multiple sclerosis	0.000265	0.000616	CcSEcCtD
Naltrexone—Infection—Prednisone—multiple sclerosis	0.000264	0.000615	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000263	0.000613	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000263	0.000613	CcSEcCtD
Naltrexone—Back pain—Methotrexate—multiple sclerosis	0.000263	0.000613	CcSEcCtD
Naltrexone—Fatigue—Dexamethasone—multiple sclerosis	0.000263	0.000613	CcSEcCtD
Naltrexone—Fatigue—Betamethasone—multiple sclerosis	0.000263	0.000613	CcSEcCtD
Naltrexone—Shock—Prednisone—multiple sclerosis	0.000261	0.000609	CcSEcCtD
Naltrexone—Pain—Betamethasone—multiple sclerosis	0.000261	0.000608	CcSEcCtD
Naltrexone—Pain—Dexamethasone—multiple sclerosis	0.000261	0.000608	CcSEcCtD
Naltrexone—Nervous system disorder—Prednisone—multiple sclerosis	0.00026	0.000607	CcSEcCtD
Naltrexone—Tachycardia—Prednisone—multiple sclerosis	0.000259	0.000604	CcSEcCtD
Naltrexone—Skin disorder—Prednisone—multiple sclerosis	0.000258	0.000601	CcSEcCtD
Naltrexone—Hyperhidrosis—Prednisone—multiple sclerosis	0.000257	0.000598	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—multiple sclerosis	0.000256	0.000597	CcSEcCtD
Naltrexone—Anorexia—Prednisone—multiple sclerosis	0.000253	0.00059	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000252	0.000588	CcSEcCtD
Naltrexone—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000251	0.000585	CcSEcCtD
Naltrexone—Feeling abnormal—Betamethasone—multiple sclerosis	0.000251	0.000585	CcSEcCtD
Naltrexone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000249	0.000581	CcSEcCtD
Naltrexone—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000249	0.000581	CcSEcCtD
Naltrexone—OPRM1—midbrain—multiple sclerosis	0.000249	0.0522	CbGeAlD
Naltrexone—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000248	0.000577	CcSEcCtD
Naltrexone—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000247	0.000576	CcSEcCtD
Naltrexone—Malaise—Methotrexate—multiple sclerosis	0.000245	0.000571	CcSEcCtD
Naltrexone—OPRM1—spinal cord—multiple sclerosis	0.000243	0.0509	CbGeAlD
Naltrexone—Urticaria—Betamethasone—multiple sclerosis	0.000242	0.000564	CcSEcCtD
Naltrexone—Urticaria—Dexamethasone—multiple sclerosis	0.000242	0.000564	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000242	0.000564	CcSEcCtD
Naltrexone—Dizziness—Prednisolone—multiple sclerosis	0.000242	0.000563	CcSEcCtD
Naltrexone—Asthenia—Triamcinolone—multiple sclerosis	0.000241	0.000562	CcSEcCtD
Naltrexone—Abdominal pain—Betamethasone—multiple sclerosis	0.000241	0.000562	CcSEcCtD
Naltrexone—Body temperature increased—Betamethasone—multiple sclerosis	0.000241	0.000562	CcSEcCtD
Naltrexone—Abdominal pain—Dexamethasone—multiple sclerosis	0.000241	0.000562	CcSEcCtD
Naltrexone—Body temperature increased—Dexamethasone—multiple sclerosis	0.000241	0.000562	CcSEcCtD
Naltrexone—Asthenia—Methylprednisolone—multiple sclerosis	0.000241	0.000561	CcSEcCtD
Naltrexone—Insomnia—Prednisone—multiple sclerosis	0.00024	0.00056	CcSEcCtD
Naltrexone—Paraesthesia—Prednisone—multiple sclerosis	0.000238	0.000556	CcSEcCtD
Naltrexone—Pruritus—Triamcinolone—multiple sclerosis	0.000238	0.000554	CcSEcCtD
Naltrexone—Cough—Methotrexate—multiple sclerosis	0.000237	0.000553	CcSEcCtD
Naltrexone—Pruritus—Methylprednisolone—multiple sclerosis	0.000237	0.000553	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—multiple sclerosis	0.000236	0.000549	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—multiple sclerosis	0.000231	0.000539	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—multiple sclerosis	0.000231	0.000539	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—multiple sclerosis	0.000231	0.000539	CcSEcCtD
Naltrexone—Decreased appetite—Prednisone—multiple sclerosis	0.000231	0.000538	CcSEcCtD
Naltrexone—Rash—Prednisolone—multiple sclerosis	0.00023	0.000537	CcSEcCtD
Naltrexone—Dermatitis—Prednisolone—multiple sclerosis	0.00023	0.000536	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00023	0.000536	CcSEcCtD
Naltrexone—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000229	0.000535	CcSEcCtD
Naltrexone—OPRD1—brain—multiple sclerosis	0.000229	0.0481	CbGeAlD
Naltrexone—Fatigue—Prednisone—multiple sclerosis	0.000229	0.000533	CcSEcCtD
Naltrexone—Headache—Prednisolone—multiple sclerosis	0.000229	0.000533	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—multiple sclerosis	0.000229	0.000533	CcSEcCtD
Naltrexone—Constipation—Prednisone—multiple sclerosis	0.000227	0.000529	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—multiple sclerosis	0.000224	0.000521	CcSEcCtD
Naltrexone—Dizziness—Triamcinolone—multiple sclerosis	0.000222	0.000518	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000222	0.000517	CcSEcCtD
Naltrexone—Dizziness—Methylprednisolone—multiple sclerosis	0.000222	0.000517	CcSEcCtD
Naltrexone—Infection—Methotrexate—multiple sclerosis	0.00022	0.000514	CcSEcCtD
Naltrexone—OPRK1—brain—multiple sclerosis	0.00022	0.0461	CbGeAlD
Naltrexone—Feeling abnormal—Prednisone—multiple sclerosis	0.000219	0.00051	CcSEcCtD
Naltrexone—Asthenia—Betamethasone—multiple sclerosis	0.000219	0.00051	CcSEcCtD
Naltrexone—Asthenia—Dexamethasone—multiple sclerosis	0.000219	0.00051	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—multiple sclerosis	0.000218	0.000507	CcSEcCtD
Naltrexone—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000217	0.000506	CcSEcCtD
Naltrexone—Nausea—Prednisolone—multiple sclerosis	0.000217	0.000506	CcSEcCtD
Naltrexone—Pruritus—Dexamethasone—multiple sclerosis	0.000216	0.000503	CcSEcCtD
Naltrexone—Pruritus—Betamethasone—multiple sclerosis	0.000216	0.000503	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—multiple sclerosis	0.000216	0.000502	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000215	0.0005	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000214	0.00144	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCR2—multiple sclerosis	0.000214	0.00144	CbGpPWpGaD
Naltrexone—Vomiting—Triamcinolone—multiple sclerosis	0.000214	0.000498	CcSEcCtD
Naltrexone—Vomiting—Methylprednisolone—multiple sclerosis	0.000213	0.000497	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—LINGO1—multiple sclerosis	0.000213	0.00144	CbGpPWpGaD
Naltrexone—Rash—Triamcinolone—multiple sclerosis	0.000212	0.000494	CcSEcCtD
Naltrexone—Dermatitis—Triamcinolone—multiple sclerosis	0.000212	0.000493	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—multiple sclerosis	0.000212	0.000493	CcSEcCtD
Naltrexone—Rash—Methylprednisolone—multiple sclerosis	0.000211	0.000493	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000211	0.00142	CbGpPWpGaD
Naltrexone—Dermatitis—Methylprednisolone—multiple sclerosis	0.000211	0.000492	CcSEcCtD
Naltrexone—Urticaria—Prednisone—multiple sclerosis	0.000211	0.000492	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000211	0.00142	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TAGAP—multiple sclerosis	0.000211	0.00142	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—POMC—multiple sclerosis	0.000211	0.00142	CbGpPWpGaD
Naltrexone—Headache—Triamcinolone—multiple sclerosis	0.00021	0.000491	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—CXCL10—multiple sclerosis	0.00021	0.00142	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CD80—multiple sclerosis	0.00021	0.00142	CbGpPWpGaD
Naltrexone—Headache—Methylprednisolone—multiple sclerosis	0.00021	0.000489	CcSEcCtD
Naltrexone—Abdominal pain—Prednisone—multiple sclerosis	0.00021	0.000489	CcSEcCtD
Naltrexone—Body temperature increased—Prednisone—multiple sclerosis	0.00021	0.000489	CcSEcCtD
Naltrexone—Diarrhoea—Betamethasone—multiple sclerosis	0.000209	0.000486	CcSEcCtD
Naltrexone—Diarrhoea—Dexamethasone—multiple sclerosis	0.000209	0.000486	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CCL5—multiple sclerosis	0.000206	0.00139	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000206	0.00139	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000205	0.00138	CbGpPWpGaD
Naltrexone—OPRM1—nervous system—multiple sclerosis	0.000204	0.0429	CbGeAlD
Naltrexone—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000202	0.000471	CcSEcCtD
Naltrexone—Dizziness—Dexamethasone—multiple sclerosis	0.000202	0.00047	CcSEcCtD
Naltrexone—Dizziness—Betamethasone—multiple sclerosis	0.000202	0.00047	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—CCR1—multiple sclerosis	0.000202	0.00136	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000202	0.00136	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000201	0.00135	CbGpPWpGaD
Naltrexone—Insomnia—Methotrexate—multiple sclerosis	0.000201	0.000468	CcSEcCtD
Naltrexone—Nausea—Triamcinolone—multiple sclerosis	0.0002	0.000465	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—multiple sclerosis	0.000199	0.000464	CcSEcCtD
Naltrexone—Nausea—Methylprednisolone—multiple sclerosis	0.000199	0.000464	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—multiple sclerosis	0.000198	0.000461	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CNR1—multiple sclerosis	0.000197	0.00133	CbGpPWpGaD
Naltrexone—Somnolence—Methotrexate—multiple sclerosis	0.000197	0.00046	CcSEcCtD
Naltrexone—OPRM1—central nervous system—multiple sclerosis	0.000197	0.0413	CbGeAlD
Naltrexone—OPRM1—Signaling by GPCR—RGS1—multiple sclerosis	0.000196	0.00132	CbGpPWpGaD
Naltrexone—Hypersensitivity—Prednisone—multiple sclerosis	0.000196	0.000456	CcSEcCtD
Naltrexone—Vomiting—Dexamethasone—multiple sclerosis	0.000194	0.000452	CcSEcCtD
Naltrexone—Vomiting—Betamethasone—multiple sclerosis	0.000194	0.000452	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—multiple sclerosis	0.000193	0.00045	CcSEcCtD
Naltrexone—Rash—Dexamethasone—multiple sclerosis	0.000192	0.000448	CcSEcCtD
Naltrexone—Rash—Betamethasone—multiple sclerosis	0.000192	0.000448	CcSEcCtD
Naltrexone—Dermatitis—Dexamethasone—multiple sclerosis	0.000192	0.000448	CcSEcCtD
Naltrexone—Dermatitis—Betamethasone—multiple sclerosis	0.000192	0.000448	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000192	0.000446	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—multiple sclerosis	0.000191	0.000446	CcSEcCtD
Naltrexone—Headache—Betamethasone—multiple sclerosis	0.000191	0.000445	CcSEcCtD
Naltrexone—Headache—Dexamethasone—multiple sclerosis	0.000191	0.000445	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000191	0.00129	CbGpPWpGaD
Naltrexone—Asthenia—Prednisone—multiple sclerosis	0.00019	0.000444	CcSEcCtD
Naltrexone—Pain—Methotrexate—multiple sclerosis	0.00019	0.000442	CcSEcCtD
Naltrexone—Pruritus—Prednisone—multiple sclerosis	0.000188	0.000438	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000188	0.00126	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000188	0.00126	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000187	0.00126	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000187	0.00126	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GPR65—multiple sclerosis	0.000186	0.00126	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCR5—multiple sclerosis	0.000186	0.00125	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TAGAP—multiple sclerosis	0.000185	0.00125	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—S1PR1—multiple sclerosis	0.000184	0.00124	CbGpPWpGaD
Naltrexone—Feeling abnormal—Methotrexate—multiple sclerosis	0.000183	0.000426	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000182	0.00123	CbGpPWpGaD
Naltrexone—Diarrhoea—Prednisone—multiple sclerosis	0.000182	0.000423	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000181	0.000423	CcSEcCtD
Naltrexone—Nausea—Dexamethasone—multiple sclerosis	0.000181	0.000422	CcSEcCtD
Naltrexone—Nausea—Betamethasone—multiple sclerosis	0.000181	0.000422	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—CCL5—multiple sclerosis	0.000181	0.00122	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000181	0.00122	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LINGO1—multiple sclerosis	0.00018	0.00121	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GPC5—multiple sclerosis	0.000179	0.00121	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—POMC—multiple sclerosis	0.000178	0.0012	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000178	0.0012	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP27B1—multiple sclerosis	0.000178	0.0012	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP24A1—multiple sclerosis	0.000178	0.0012	CbGpPWpGaD
Naltrexone—Urticaria—Methotrexate—multiple sclerosis	0.000176	0.000411	CcSEcCtD
Naltrexone—Dizziness—Prednisone—multiple sclerosis	0.000176	0.000409	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—multiple sclerosis	0.000175	0.000409	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—multiple sclerosis	0.000175	0.000409	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000174	0.00117	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL13—multiple sclerosis	0.00017	0.00115	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR1—multiple sclerosis	0.00017	0.00115	CbGpPWpGaD
Naltrexone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000169	0.00114	CbGpPWpGaD
Naltrexone—Vomiting—Prednisone—multiple sclerosis	0.000169	0.000393	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000168	0.00113	CbGpPWpGaD
Naltrexone—Rash—Prednisone—multiple sclerosis	0.000167	0.00039	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000167	0.00113	CbGpPWpGaD
Naltrexone—Dermatitis—Prednisone—multiple sclerosis	0.000167	0.00039	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—IL6—multiple sclerosis	0.000167	0.00112	CbGpPWpGaD
Naltrexone—Headache—Prednisone—multiple sclerosis	0.000166	0.000388	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	0.000166	0.00112	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL3—multiple sclerosis	0.000164	0.0011	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000164	0.0011	CbGpPWpGaD
Naltrexone—Hypersensitivity—Methotrexate—multiple sclerosis	0.000163	0.000381	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000163	0.0011	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCR5—multiple sclerosis	0.000163	0.0011	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPC5—multiple sclerosis	0.000162	0.00109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—S1PR1—multiple sclerosis	0.000162	0.00109	CbGpPWpGaD
Naltrexone—Asthenia—Methotrexate—multiple sclerosis	0.000159	0.000371	CcSEcCtD
Naltrexone—Nausea—Prednisone—multiple sclerosis	0.000158	0.000368	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000158	0.00106	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GPC5—multiple sclerosis	0.000157	0.00106	CbGpPWpGaD
Naltrexone—Pruritus—Methotrexate—multiple sclerosis	0.000157	0.000366	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—RGS1—multiple sclerosis	0.000157	0.00106	CbGpPWpGaD
Naltrexone—OPRM1—brain—multiple sclerosis	0.000156	0.0328	CbGeAlD
Naltrexone—OPRM1—Signaling Pathways—TAGAP—multiple sclerosis	0.000156	0.00105	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TGFB1—multiple sclerosis	0.000154	0.00104	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL5—multiple sclerosis	0.000153	0.00103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCR3—multiple sclerosis	0.000152	0.00103	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000152	0.00103	CbGpPWpGaD
Naltrexone—Diarrhoea—Methotrexate—multiple sclerosis	0.000152	0.000354	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CNR1—multiple sclerosis	0.000151	0.00101	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GPR65—multiple sclerosis	0.000148	0.001	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	0.000148	0.000999	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCR2—multiple sclerosis	0.000148	0.000999	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL2—multiple sclerosis	0.000148	0.000995	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000147	0.000991	CbGpPWpGaD
Naltrexone—Dizziness—Methotrexate—multiple sclerosis	0.000147	0.000342	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000146	0.000984	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—POMC—multiple sclerosis	0.000145	0.00098	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL3—multiple sclerosis	0.000144	0.000968	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000143	0.000964	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCL2—multiple sclerosis	0.000142	0.000959	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000142	0.000956	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000141	0.000954	CbGpPWpGaD
Naltrexone—Vomiting—Methotrexate—multiple sclerosis	0.000141	0.000329	CcSEcCtD
Naltrexone—Rash—Methotrexate—multiple sclerosis	0.00014	0.000326	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—multiple sclerosis	0.00014	0.000326	CcSEcCtD
Naltrexone—Headache—Methotrexate—multiple sclerosis	0.000139	0.000324	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000138	0.000933	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000138	0.000932	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCR5—multiple sclerosis	0.000138	0.000929	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RGS1—multiple sclerosis	0.000137	0.000926	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CNR1—multiple sclerosis	0.000137	0.000922	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—S1PR1—multiple sclerosis	0.000136	0.00092	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR1—multiple sclerosis	0.000136	0.000916	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL13—multiple sclerosis	0.000136	0.000916	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000136	0.000914	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—RRM1—multiple sclerosis	0.000135	0.000907	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCR3—multiple sclerosis	0.000134	0.0009	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GPC5—multiple sclerosis	0.000133	0.000895	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CNR1—multiple sclerosis	0.000132	0.00089	CbGpPWpGaD
Naltrexone—Nausea—Methotrexate—multiple sclerosis	0.000132	0.000307	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—GPR65—multiple sclerosis	0.00013	0.000878	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR2—multiple sclerosis	0.00013	0.000876	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000129	0.000867	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—POMC—multiple sclerosis	0.000127	0.000859	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000125	0.000843	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCL2—multiple sclerosis	0.000125	0.000841	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000124	0.000838	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000123	0.00083	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL3—multiple sclerosis	0.000121	0.000818	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000121	0.000815	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CNR1—multiple sclerosis	0.00012	0.000808	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL13—multiple sclerosis	0.000119	0.000803	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR1—multiple sclerosis	0.000119	0.000803	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000119	0.000801	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000117	0.000788	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCL5—multiple sclerosis	0.000117	0.000787	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RGS1—multiple sclerosis	0.000116	0.000783	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SRM—multiple sclerosis	0.000116	0.000779	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	0.000115	0.000776	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCR3—multiple sclerosis	0.000113	0.000761	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000112	0.000756	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CNR1—multiple sclerosis	0.000112	0.000752	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GPR65—multiple sclerosis	0.00011	0.000742	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR2—multiple sclerosis	0.00011	0.00074	CbGpPWpGaD
Naltrexone—ABCB1—retina—multiple sclerosis	0.000109	0.0228	CbGeAlD
Naltrexone—OPRK1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000108	0.000728	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—POMC—multiple sclerosis	0.000108	0.000726	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—multiple sclerosis	0.000108	0.000725	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL5—multiple sclerosis	0.000106	0.000714	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL2—multiple sclerosis	0.000105	0.000711	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000105	0.000709	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000104	0.000698	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCL5—multiple sclerosis	0.000102	0.00069	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CNR1—multiple sclerosis	0.000101	0.000683	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR1—multiple sclerosis	0.000101	0.000678	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL13—multiple sclerosis	0.000101	0.000678	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.0001	0.000677	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	9.91e-05	0.000668	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL3—multiple sclerosis	9.68e-05	0.000652	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCR5—multiple sclerosis	9.54e-05	0.000644	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2RA—multiple sclerosis	9.41e-05	0.000634	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTGER4—multiple sclerosis	9.31e-05	0.000628	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL5—multiple sclerosis	9.29e-05	0.000626	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR5—multiple sclerosis	9.22e-05	0.000621	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PGR—multiple sclerosis	9.17e-05	0.000618	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL10—multiple sclerosis	9.12e-05	0.000615	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2RA—multiple sclerosis	9.08e-05	0.000612	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCR3—multiple sclerosis	8.99e-05	0.000606	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CD28—multiple sclerosis	8.91e-05	0.000601	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR2—multiple sclerosis	8.75e-05	0.00059	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCL5—multiple sclerosis	8.65e-05	0.000583	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL3—multiple sclerosis	8.48e-05	0.000572	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR5—multiple sclerosis	8.37e-05	0.000564	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2RA—multiple sclerosis	8.25e-05	0.000556	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—POMC—multiple sclerosis	8.21e-05	0.000554	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTGER4—multiple sclerosis	8.17e-05	0.000551	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP24A1—multiple sclerosis	8.15e-05	0.000549	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP27B1—multiple sclerosis	8.15e-05	0.000549	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CNR1—multiple sclerosis	8.08e-05	0.000544	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PGR—multiple sclerosis	8.04e-05	0.000542	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCR3—multiple sclerosis	7.89e-05	0.000532	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL5—multiple sclerosis	7.85e-05	0.000529	CbGpPWpGaD
Naltrexone—ABCB1—medulla oblongata—multiple sclerosis	7.85e-05	0.0165	CbGeAlD
Naltrexone—OPRK1—Signaling Pathways—CD28—multiple sclerosis	7.81e-05	0.000527	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR5—multiple sclerosis	7.79e-05	0.000525	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—BCHE—multiple sclerosis	7.73e-05	0.000521	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	7.68e-05	0.000518	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR2—multiple sclerosis	7.67e-05	0.000517	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—POMC—multiple sclerosis	7.46e-05	0.000503	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPC5—multiple sclerosis	7.45e-05	0.000502	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL2—multiple sclerosis	7.3e-05	0.000492	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL10—multiple sclerosis	7.27e-05	0.00049	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—POMC—multiple sclerosis	7.2e-05	0.000486	CbGpPWpGaD
Naltrexone—ABCB1—midbrain—multiple sclerosis	7.17e-05	0.0151	CbGeAlD
Naltrexone—OPRM1—Signaling Pathways—CCL3—multiple sclerosis	7.17e-05	0.000483	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CNR1—multiple sclerosis	7.08e-05	0.000477	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR5—multiple sclerosis	7.07e-05	0.000477	CbGpPWpGaD
Naltrexone—ABCB1—spinal cord—multiple sclerosis	7e-05	0.0147	CbGeAlD
Naltrexone—OPRM1—Signaling by GPCR—IL2RA—multiple sclerosis	6.97e-05	0.00047	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTGER4—multiple sclerosis	6.9e-05	0.000465	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PGR—multiple sclerosis	6.8e-05	0.000458	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCR3—multiple sclerosis	6.67e-05	0.000449	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—TYK2—multiple sclerosis	6.63e-05	0.000447	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD28—multiple sclerosis	6.6e-05	0.000445	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—POMC—multiple sclerosis	6.54e-05	0.000441	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR2—multiple sclerosis	6.48e-05	0.000437	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL2—multiple sclerosis	6.4e-05	0.000432	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL10—multiple sclerosis	6.38e-05	0.00043	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CD86—multiple sclerosis	6.36e-05	0.000429	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL5—multiple sclerosis	6.26e-05	0.000422	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—RRM1—multiple sclerosis	6.17e-05	0.000416	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—POMC—multiple sclerosis	6.09e-05	0.00041	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—multiple sclerosis	6.07e-05	0.000409	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CNR1—multiple sclerosis	5.98e-05	0.000403	CbGpPWpGaD
Naltrexone—ABCB1—nervous system—multiple sclerosis	5.9e-05	0.0124	CbGeAlD
Naltrexone—OPRK1—Signaling by GPCR—TYK2—multiple sclerosis	5.81e-05	0.000392	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SPP1—multiple sclerosis	5.8e-05	0.000391	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	5.7e-05	0.000384	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	5.68e-05	0.000383	CbGpPWpGaD
Naltrexone—ABCB1—central nervous system—multiple sclerosis	5.68e-05	0.0119	CbGeAlD
Naltrexone—OPRD1—Signaling Pathways—CCR5—multiple sclerosis	5.64e-05	0.00038	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CD86—multiple sclerosis	5.57e-05	0.000376	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	5.57e-05	0.000376	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2RA—multiple sclerosis	5.56e-05	0.000375	CbGpPWpGaD
Naltrexone—ABCB1—cerebellum—multiple sclerosis	5.55e-05	0.0116	CbGeAlD
Naltrexone—OPRM1—Signaling by GPCR—POMC—multiple sclerosis	5.53e-05	0.000373	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—multiple sclerosis	5.51e-05	0.000372	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL5—multiple sclerosis	5.49e-05	0.00037	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL2—multiple sclerosis	5.41e-05	0.000365	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL10—multiple sclerosis	5.39e-05	0.000363	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—multiple sclerosis	5.33e-05	0.000359	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	5.31e-05	0.000358	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—multiple sclerosis	5.13e-05	0.000346	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SPP1—multiple sclerosis	5.08e-05	0.000343	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR5—multiple sclerosis	4.94e-05	0.000333	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—TYK2—multiple sclerosis	4.91e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2RA—multiple sclerosis	4.87e-05	0.000329	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—multiple sclerosis	4.84e-05	0.000326	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD86—multiple sclerosis	4.71e-05	0.000318	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—multiple sclerosis	4.65e-05	0.000313	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL5—multiple sclerosis	4.64e-05	0.000313	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CD80—multiple sclerosis	4.64e-05	0.000313	CbGpPWpGaD
Naltrexone—ABCB1—brain—multiple sclerosis	4.51e-05	0.00946	CbGeAlD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—multiple sclerosis	4.5e-05	0.000303	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—multiple sclerosis	4.5e-05	0.000303	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—POMC—multiple sclerosis	4.41e-05	0.000297	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL2—multiple sclerosis	4.31e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SPP1—multiple sclerosis	4.3e-05	0.00029	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK1—multiple sclerosis	4.22e-05	0.000284	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR5—multiple sclerosis	4.18e-05	0.000282	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2RA—multiple sclerosis	4.12e-05	0.000278	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—multiple sclerosis	4.09e-05	0.000276	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CD80—multiple sclerosis	4.07e-05	0.000274	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—POMC—multiple sclerosis	3.99e-05	0.000269	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TYK2—multiple sclerosis	3.92e-05	0.000264	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—POMC—multiple sclerosis	3.86e-05	0.000261	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—multiple sclerosis	3.8e-05	0.000256	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL2—multiple sclerosis	3.78e-05	0.000255	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK1—multiple sclerosis	3.7e-05	0.000249	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—multiple sclerosis	3.64e-05	0.000246	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.57e-05	0.00024	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BCHE—multiple sclerosis	3.55e-05	0.000239	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD80—multiple sclerosis	3.44e-05	0.000232	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TYK2—multiple sclerosis	3.43e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—POMC—multiple sclerosis	3.27e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—multiple sclerosis	3.26e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—multiple sclerosis	3.24e-05	0.000219	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL2—multiple sclerosis	3.2e-05	0.000215	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK1—multiple sclerosis	3.13e-05	0.000211	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—multiple sclerosis	3.08e-05	0.000208	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TYK2—multiple sclerosis	2.9e-05	0.000196	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—multiple sclerosis	2.86e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—multiple sclerosis	2.84e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—multiple sclerosis	2.74e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—multiple sclerosis	2.7e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—multiple sclerosis	2.55e-05	0.000172	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—multiple sclerosis	2.54e-05	0.000171	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK1—multiple sclerosis	2.49e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—multiple sclerosis	2.41e-05	0.000163	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—multiple sclerosis	2.4e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—multiple sclerosis	2.4e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—multiple sclerosis	2.29e-05	0.000154	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—multiple sclerosis	2.23e-05	0.000151	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—multiple sclerosis	2.23e-05	0.00015	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK1—multiple sclerosis	2.19e-05	0.000147	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—multiple sclerosis	2.13e-05	0.000144	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—multiple sclerosis	2.03e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—multiple sclerosis	1.91e-05	0.000129	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—multiple sclerosis	1.89e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—multiple sclerosis	1.88e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK1—multiple sclerosis	1.85e-05	0.000125	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—POMC—multiple sclerosis	1.83e-05	0.000124	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—multiple sclerosis	1.68e-05	0.000113	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—multiple sclerosis	1.67e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—multiple sclerosis	1.42e-05	9.57e-05	CbGpPWpGaD
